Autres langues PharmaTher Holdings Ltd.

Actions

PHRM

CA71716H1082

Marché Fermé - Canadian Securities Exchange Autres places de cotation 21:59:59 08/05/2024			Varia. 5j.	Varia. 1 janv.
0,26 ^CAD	-1,89 %		-5,45 %	-17,46 %

23/04	PharmaTher Holdings Ltd. annonce ses résultats pour le troisième trimestre et les neuf mois terminés le 29 février 2024	CI
16/04	PharmaTher Holdings Ltd. fait le point sur sa demande prioritaire de nouveau médicament abrégé original pour la kétamine	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

PharmaTher's Sairiyo Therapeutics Completes Regulatory Package For Phase 1 Study of Reformulated Cepharanthine in Australia	01/05
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine	01/05
PharmaTher Holdings Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended February 29, 2024	23/04
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	18/04
PharmaTher Updated on its Priority Original Abbreviated New Drug Application for Ketamine	16/04
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	16/04
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	16/04
PharmaTher Provides Update For PD-001	21/02
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia	21/02
CapitalGainsReport: Foreign Stocks Under .2 With Growing Potential (TBRIF, BRHCF, FFNTF, PHRRF)	15/02
PharmaTher Provides Update on its Priority Original Abbreviated New Drug Application For Ketamine	12/02
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	12/02
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine	12/02
PharmaTher Holdings Ltd. Provides Update of Its Priority Original Abbreviated New Drug Application for Ketamine	12/02
PharmaTher Holdings Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2023	27/01
PharmaTher Provided Update for Expected FDA Approval of Ketamine	10/01
PharmaTher Provides Update for Expected FDA Approval of Ketamine	10/01
PharmaTher Holdings Ltd. Provides an Update for Its Lead Drug, Ketamine	10/01
PharmaTher Holdings Ltd. Reports Earnings Results for the First Quarter Ended August 31, 2023	31/10/23
PharmaTher Holdings Ltd. Reports Earnings Results for the Full Year Ended May 31, 2023	29/09/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues PharmaTher Holdings Ltd.

Actions

PHRM

CA71716H1082

Autres langues

Filtres